bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) is one of 39 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare bioAffinity Technologies to related businesses based on the strength of its dividends, profitability, risk, earnings, institutional ownership, valuation and analyst recommendations.
Institutional and Insider Ownership
1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are held by institutional investors. 44.3% of bioAffinity Technologies shares are held by insiders. Comparatively, 16.7% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares bioAffinity Technologies and its peers top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
bioAffinity Technologies | $2.53 million | -$7.94 million | -2.72 |
bioAffinity Technologies Competitors | $1.55 billion | $101.44 million | 9.11 |
Analyst Ratings
This is a breakdown of recent ratings and target prices for bioAffinity Technologies and its peers, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
bioAffinity Technologies Competitors | 50 | 817 | 1303 | 31 | 2.60 |
As a group, “Commercial physical research” companies have a potential upside of 11.25%. Given bioAffinity Technologies’ peers higher possible upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its peers.
Profitability
This table compares bioAffinity Technologies and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
bioAffinity Technologies | -313.34% | -107.20% | -84.10% |
bioAffinity Technologies Competitors | -249.52% | -18.54% | -11.18% |
Volatility and Risk
bioAffinity Technologies has a beta of 3.93, meaning that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ peers have a beta of 6.02, meaning that their average share price is 502% more volatile than the S&P 500.
Summary
bioAffinity Technologies peers beat bioAffinity Technologies on 9 of the 10 factors compared.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.